News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Grannus BioSciences Limited Announces Agreement For Clinical And Preclinical Molecules


10/21/2005 6:41:05 PM

Grannus BioSciences Ltd, a privately held biotechnology company developing anti-inflammatory products, announced today two separate agreements with Strathclyde University the first involving a clinical stage compound for use in certain dermatologic and cancer applications. Under a second and separate agreement, Grannus will have an option to as many as six small molecules for development as potential anti-inflammatory pharmaceuticals. The company will collaborate with the Strathclyde Institute for Drug Research (SIDR) which discovered the compounds. Financial terms were not disclosed.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES